Sangamo Therapeutics Inc (NASDAQ:SGMO) has been given an average rating of “Hold” by the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $12.67.

A number of research firms have recently issued reports on SGMO. Wedbush reaffirmed a “hold” rating and set a $11.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday. Zacks Investment Research raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. ValuEngine raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. BidaskClub raised shares of Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 30th. Finally, HC Wainwright began coverage on shares of Sangamo Therapeutics in a report on Monday, August 26th. They set a “buy” rating and a $16.00 price objective for the company.

Shares of NASDAQ SGMO traded down $0.24 during mid-day trading on Monday, reaching $9.45. 707,200 shares of the company were exchanged, compared to its average volume of 1,792,778. Sangamo Therapeutics has a 52 week low of $6.26 and a 52 week high of $13.91. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $1.13 billion, a PE ratio of -13.50 and a beta of 2.79. The company’s 50 day moving average price is $8.94 and its 200 day moving average price is $10.32.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10. Sangamo Therapeutics had a negative net margin of 159.12% and a negative return on equity of 30.33%. The company had revenue of $21.96 million during the quarter, compared to the consensus estimate of $12.16 million. During the same period in the previous year, the firm posted ($0.13) EPS. The firm’s revenue was down 6.8% compared to the same quarter last year. On average, sell-side analysts predict that Sangamo Therapeutics will post -1.21 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of SGMO. Quantitative Systematic Strategies LLC bought a new stake in Sangamo Therapeutics in the second quarter worth $126,000. Steward Partners Investment Advisory LLC bought a new stake in Sangamo Therapeutics in the second quarter worth $50,000. Virginia Retirement Systems ET AL lifted its stake in Sangamo Therapeutics by 13.6% in the second quarter. Virginia Retirement Systems ET AL now owns 20,900 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 2,500 shares during the last quarter. Creative Planning lifted its stake in Sangamo Therapeutics by 91.1% in the second quarter. Creative Planning now owns 55,104 shares of the biopharmaceutical company’s stock worth $593,000 after purchasing an additional 26,265 shares during the last quarter. Finally, Bailard Inc. lifted its stake in Sangamo Therapeutics by 12.5% in the second quarter. Bailard Inc. now owns 175,600 shares of the biopharmaceutical company’s stock worth $1,891,000 after purchasing an additional 19,500 shares during the last quarter. 69.31% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Recommended Story: Risk Tolerance

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.